How to appeal an Aetna men's sexual health — trt + ed denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Aetna-specific note: Owned by CVS Health since 2018. CVS Caremark is the PBM. Aetna ASA administers self-funded ERISA plans. Meritain Health is Aetna's TPA brand.

What Aetna's policy requires for men's sexual health — trt + ed

Cited policy: Aetna CPB on Oral Testosterone Undecanoate (Jatenzo / Tlando / Kyzatrex)

Adult male meeting AUA 2018 / Endo Society 2018 hypogonadism criteria (≥2 AM total-T <300 ng/dL or <264 LC-MS/MS + symptoms). LH/FSH documented. PSA + hematocrit baseline. Trial / contraindication / intolerance to topical or injectable T preferred for some plans. Not for hypogonadism due to age alone — but symptom + threshold combination qualifies. Reauth at 6 mo with response.

How Aetna denies men's sexual health — trt + ed — and how to counter it

Where Aetna pushes back: 1) Step therapy — must fail topical or injectable first; 2) Considered experimental; 3) CV / hepatic risk concerns.

Counter-arguments that hold up: All three oral testosterone undecanoate products are FDA-approved: Jatenzo Mar 27 2019, Tlando Mar 28 2022, Kyzatrex Jul 27 2022. Pivotal trials (Swerdloff JCEM 2020 inTUne for Jatenzo) showed ~85-88% achieving normal T range. Lymphatic absorption avoids first-pass hepatotoxicity of older oral methyltestosterone. Specific clinical advantages over topicals: NO transfer risk to women/children (cite if young children at home or pregnant partner); over injectables: NO injection burden + adherence + avoids deep-IM cypionate peak/trough excursions. CV safety supported in TRAVERSE NEJM 2023 framework (testosterone class). Step-therapy carve-out justified when transfer risk or injection-aversion documented.

What Aetna typically denies for men's sexual health — trt + ed

Across Aetna's commercial and Medicare books, denials cluster around a small number of patterns. For men's sexual health — trt + ed, expect:

• UM-2575 medical necessity denials
• Prior auth absent
• Step therapy on specialty drugs
• Out-of-network ER reduction

Treatments most often denied in this category

These are the men's sexual health — trt + ed treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Testosterone cypionate
• Testosterone enanthate
• Aveed (TU IM)
• Xyosted (TE SC)
• Testosterone gel
• Axiron (T solution)

How to submit the appeal to Aetna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Aetna cited in the denial.
3. File the appeal through Aetna's portal (members: https://www.aetna.com ; providers: https://www.aetnaprovider.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Aetna's prior-authorization criteria by drug: Aetna PA criteria on ApprovalHelp.